Barclays Cuts Vitamin Shoppe (NYSE:VSI) Stock To a Underweight Rating

September 8, 2018 - By Vernon Prom

Vitamin Shoppe, Inc. (NYSE:VSI) Logo

Vitamin Shoppe (NYSE:VSI) Receives a Downgrade

Stock analysts at Barclays’s equities research division lowered the rating for shares of Vitamin Shoppe (NYSE:VSI) from a Equal Weight to a Underweight on Friday morning.

The stock decreased 1.22% or $0.15 during the last trading session, reaching $12.15. About 785,601 shares traded or 28.32% up from the average. Vitamin Shoppe, Inc. (NYSE:VSI) has declined 54.35% since September 8, 2017 and is downtrending. It has underperformed by 66.92% the S&P500.

Analysts await Vitamin Shoppe, Inc. (NYSE:VSI) to report earnings on November, 14. They expect $0.20 EPS, up 766.67 % or $0.23 from last year’s $-0.03 per share. VSI’s profit will be $4.80M for 15.19 P/E if the $0.20 EPS becomes a reality. After $0.31 actual EPS reported by Vitamin Shoppe, Inc. for the previous quarter, Wall Street now forecasts -35.48 % negative EPS growth.

Vitamin Shoppe, Inc., through its subsidiaries, operates as a omni-channel specialty retailer and contract maker of nutritional products in the United States and internationally. The company has market cap of $291.84 million. It operates in two divisions, Retail and Manufacturing. It currently has negative earnings. The firm provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

More recent Vitamin Shoppe, Inc. (NYSE:VSI) news were published by: which released: “Natural And Specialty Retail Hemp-Derived CBD Sales Projected To Grow By More Than 600% By 2022” on August 29, 2018. Also published the news titled: “The Vitamin Shoppe introduces KETO HQ nationwide” on August 29, 2018.‘s news article titled: “25 Stocks Moving In Friday’s Pre-Market Session” with publication date: September 07, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.